Drugs / tasadenoturev
tasadenoturev
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07444606 | Aug 2026 → Jan 2027 expected | melanoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03896568 | Feb 2019 → Sep 2027 expected | anaplastic astrocytoma, gliosarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03178032 | May 2017 → Jan 2021 | brain stem glioma | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 1 | NCT02197169 | Sep 2014 → Mar 2018 | malignant glioma | DNAtrix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00805376 | Feb 2009 → Feb 2015 | brain cancer | DNAtrix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00562003 | Jun 2007 → May 2009 | ovarian cancer, primary peritoneal carcinoma | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07424092 | May 2026 → May 2029 expected | embryonal neoplasm, ependymoma, high grade astrocytic tumor | Clinica Universidad de Navarra, Universidad de Navarra | Recruiting | No outcome recorded |
| Phase 2 | NCT05009992 | Oct 2021 → Dec 2027 expected | diffuse midline glioma, H3 K27M-mutant, grade III glioma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2 | NCT02798406 | Oct 2016 → Mar 2021 | gliosarcoma | DNAtrix, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tasadenoturev | “Purpose DNX-2401 (Delta-24-RGD; tasadenoturev) is a tumor-selective, replication-competent oncolytic adenovirus.” PMID 29432077 ↗ Feb 2018 |
| Known as | Ad5-delta24RGD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00562003 ↗ |
| Known as | Delta-24-RGD | “Purpose DNX-2401 (Delta-24-RGD; tasadenoturev) is a tumor-selective, replication-competent oncolytic adenovirus.” PMID 29432077 ↗ Feb 2018 |
| Known as | DNX-2401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07424092 ↗ |
| Route | Other | “intraperitoneal delivery” NCT00562003 ↗ |